Methoxymethane（DME） Pharma Grade API is supplied as a colourless liquefied gas under pressure. The product is released in two models, DME-PG-99.9 and DME-PG-99.5. DME-PG-99.9 is applied as a volatile processing solvent, granulation fluid, and propellant in tablet, capsule, granule, and injectable process streams; DME-PG-99.5 is restricted to non-sterile granulation where a slightly wider methanol specification is acceptable. Methoxymethane has a molecular weight of 46.07 g/mol, a boiling point of −24.8 °C at 101.3 kPa, and a vapour pressure of 510 kPa at 20 °C. The designations “Oral” and “Injectable” refer to the manufacturing route in which the substance is used, not to direct administration. The material must be removed from finished oral solid and injectable matrices to residual levels justified under ICH Q3C; typical release limits for water and methanol are ≤50 ppm, with non-volatile residue ≤10 ppm. Because methoxymethane is not generally listed as an active substance in the European Pharmacopoeia, the API designation is dossier-dependent; the product is more commonly classified as a pharmaceutical-grade excipient or propellant.

How Does Pharmacopoeial-Grade DME Differ from Technical-Grade Dimethyl Ether?

Technical-grade dimethyl ether is produced for fuel and aerosol propellant markets and may contain methanol, water, sulfur odourants, and higher hydrocarbons. Pharmaceutical-grade DME is purified by molecular-sieve dehydration and fractional distillation to remove polar and non-polar impurities. The release specification is therefore more restrictive. Purity is ≥99.9% area by GC-FID, methanol ≤50 ppm, water ≤50 ppm, non-volatile residue ≤10 ppm, and sulfur species ≤1 ppm. The chromatographic method is validated per ICH Q2(R1) and Ph. Eur. 2.2.28, using a flame ionisation detector and a porous-layer open tubular column with an internal diameter of 0.32 mm. Water is determined by Karl Fischer coulometry with a drying oven interface at 110 °C per Ph. Eur. 2.5.32. Non-volatile residue is measured gravimetrically after controlled evaporation of 100 mL product at 40 °C under nitrogen sweep per Ph. Eur. 2.4.16. No odourant is added to the pharmaceutical grade, in contrast to fuel-grade DME.

Representative release specification:

The limits are applied to each lot after cylinder filling. Cylinders are stainless steel with pharmaceutical gas service cleaning and are not reused for technical-grade products. Batch-to-batch variability is controlled by verifying the distillation column bottom temperature and reflux ratio during purification; typical column overhead pressure is maintained at 0.8 MPa, with the condenser at 10–15 °C. Residual solvent analysis of finished dosage forms may be performed per USP 〈467〉 and Ph. Eur. 5.4.

When Tablet and Capsule Processing Requires a Low-Temperature Volatile Granulation Solvent

For moisture-sensitive actives, DME is metered into a high-shear granulator equipped with explosion relief panels, nitrogen inerting, and an infrared LEL sensor set to alarm at 1.0% v/v, equivalent to 30% of the lower explosive limit of 3.4% v/v. Typical granulator conditions are impeller speeds of 100–300 rpm and chopper speeds of 1500–3000 rpm; the exact values depend on bowl size and end-point torque. DME serves as the granulating fluid and can dissolve or disperse binders such as povidone or hydroxypropyl cellulose. Because its boiling point is −24.8 °C, solvent removal is performed in a vacuum tray dryer or rotary vacuum dryer at 30–35 °C under a pressure of 10–20 kPa. This compares with ethanol (78 °C) and acetone (56 °C) and reduces thermal exposure for thermolabile actives. Dried granules are milled through a 500–800 µm sieve and transferred to tablet compression or hard capsule filling. Residual DME in the granules is measured by headspace GC-FID with a limit of quantification ≤ 1 ppm. For lipid-based capsule fill formulations, DME is used as a temporary viscosity reducer and is removed before banding or sealing. Published data for this specific capsule configuration are limited; therefore, the residual level and drying endpoint are established by development batch data.

Granule drying must be conducted with continuous oxygen monitoring. The vapour phase is kept below 1.0% v/v DME, and the dryer vacuum pump is a dry-scroll or nitrogen-diluted liquid ring type. The solvent recovery train includes a refrigerated condenser operating at −40 °C and a carbon bed guard. For tablet compression, granules conditioned to a loss on drying below 0.5% are preferred; higher residual moisture can increase sticking on tablet tooling. For hard capsule filling, the granule particle size distribution is typically controlled to a D50 of 150–250 µm and a D90 below 800 µm to maintain consistent filling weight.

For injectable process streams, DME is used as a volatile process fluid for precipitation or particle-formation steps and is not present as a terminal vehicle. A stainless steel 316L jacketed vessel rated to 1.2 MPa at 50 °C holds the liquefied DME. The fluid is filtered through a 0.2 µm PTFE membrane and contacted with the active-containing organic solution in a static mixer. Precipitation occurs as DME reduces the solvent power of the carrier phase. The suspension is transferred to a vacuum filter dryer, where DME is removed at 25–35 °C until the residual level in the dried microparticle cake is ≤ 50 ppm. Compared with methylene chloride, DME avoids chlorinated hydrocarbon residues and the associated REACH restrictions. Compared with supercritical carbon dioxide, liquefied DME operates at lower pressure but introduces flammability; the installation therefore requires explosion-proof electrical classification and nitrogen blanketing. Published data for this specific configuration are limited, and injectable applications require a residue justification under ICH Q3C or Ph. Eur. 5.4.

What Differentiates DME from HFA-134a and Ether Solvents in Process Applications?

DME is a polar, low-boiling ether that differs from hydrofluoroalkane propellants in flammability and water solubility. It has a lower explosive limit of 3.4% v/v and an upper explosive limit of 27% v/v, whereas HFA-134a and HFA-227ea are non-flammable. The water solubility of DME is 71 g/L at 20 °C, which improves solvent power for polar binders but restricts open handling. In comparison, diethyl ether boils at 34.6 °C and methyl tert-butyl ether at 55.2 °C, so DME removal requires lower temperatures and shorter drying times. Unlike diethyl ether, pharmaceutical-grade DME is supplied without stabilisers such as BHT; peroxide formation is controlled by storage under nitrogen and avoidance of prolonged air contact.

DME is therefore selected when a polar, low-boiling process solvent is required and the manufacturing line is designed for flammable liquefied gases. HFA propellants remain preferable in sealed metered-dose inhaler applications where non-flammability is critical. DME is generally not selected for direct propellant replacement in metered-dose inhalers unless vapour-pressure blending with a non-flammable propellant is evaluated.

Storage and handling boundaries apply. Cylinders conforming to ISO 9809-1 are labelled per EN 1089-3 and stored in ventilated areas below 50 °C. Regulators and seals are constructed of PTFE, FFKM, or EPDM; Buna-N and natural rubber are avoided because swelling can occur. DME must be kept from strong oxidisers, chlorine, and reactive metals. Vapour extraction must maintain the concentration below 1.0% v/v, and electrical equipment must meet ATEX 2014/34/EU category II 2G IIC T2 or an equivalent national standard. Before welding or breaking connections, lines are purged with nitrogen until the outlet concentration is below 1% of the lower explosive limit. Cylinder valve outlets are protected by residual pressure valves to prevent air ingress and moisture contamination during partial use.